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Highlights 
 
 First screen of MCM9 for germline variants in Lynch-like syndrome patients. 
 
 Fifteen variants identified in a cohort of 109 Lynch-like syndrome patients. 
 
 Variants included 6 common SNPs and 9 variants of unknown significance. 
 
 Variants in MCM9 are unlikely to explain most cases of Lynch-like syndrome. 
 
 
Abstract 
 
Lynch syndrome is a hereditary cancer syndrome caused by the autosomal dominant inheritance 
of loss-of-function mutations in DNA mismatch repair (MMR) genes. Approximately one 
quarter of clinically suspected cases have no identifiable germline mutation in any MMR gene, a 
condition known as Lynch-like syndrome (LLS). MCM9 was recently identified as the DNA 
helicase in the mammalian MMR complex and loss of helicase activity results in microsatellite 
instability. We hypothesized that pathogenic variants in MCM9 may account for LLS. The 
5’UTR and coding region of MCM9 were sequenced in germline DNA of 109 Australian patients 
with LLS and variants were cross-referenced with three population-based databases (dbSNP144, 
1000 Genomes, ExAC). The functional effect of variants was assessed in silico with PolyPhen-2, 
SIFT and CONDEL. Fifteen variants that included six common SNPs and nine variants of 
unknown significance (VUS) were identified.. We conclude that VUS occur in MCM9 in a small 
proportion of LLS patients and MCM9 mutations are unlikely to explain most LLS cases. 
 
Keywords: Lynch syndrome, Lynch-like syndrome, DNA mismatch repair, MCM9, helicase.  
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Introduction 
 
Lynch syndrome is a clinical condition of early-onset cancer (average age of onset of 45 years), 
most commonly of the colorectum and endometrium, caused by the loss of DNA mismatch 
repair (MMR) function. Cancer predisposition is caused by heterozygous germline mutations in 
the DNA MMR genes [1, 2]. Most mutations occur in MLH1 (35-40%) and MSH2 (44-48%) and 
are less frequent in MSH6 (8-10%) and PMS2 (2-8%) [3, 4]. Germline MLH1 and MSH2 
mutations [5] are also associated with a higher cancer risk in comparison to other MMR genes [5, 
6, 7]. Constitutional mismatch repair-deficiency (CMMR-D) is caused by the biallelic germline 
inactivation of an MMR gene and patients present with a more severe phenotype compared to 
heterozygous germline mutation carriers. Children mainly develop haematological and brain 
malignancies as well as very early-onset colorectal cancer (CRC) [8]. 
The possibility of a Lynch syndrome diagnosis is raised by familial and/or personal 
history of cancer, and a tumor with loss of MMR protein staining by immunohistochemistry 
(IHC) and/or microsatellite instability (MSI). Diagnostic screening of the MMR genes in these 
patients, however, often fails to find a pathogenic sequence variant or a constitutional 
epimutation. Patients for whom there is a strong clinical suspicion of Lynch syndrome but no 
detectable germline mutation or epimutation in a MMR gene are categorized as having Lynch-
like syndrome (LLS) [9]. Patients with CMMR-D resulting from MSH6 or PMS2 mutations may 
not necessarily have a family history consistent with Lynch syndrome because of reduced 
penetrance of mutant alleles in heterozygous carriers [5], however, they can be distinguished 
from LLS patients by a positive germline genetic test. Recent screens of LLS cohorts indicate 
that cancers may arise from somatic mutations in MMR genes, however, the syndrome often has 
no definitive genetic explanation [10, 11]. 
MCM9 was recently identified as a helicase that is required for mammalian DNA MMR. 
MCM9 recruitment to chromatin is MSH2-dependent and stimulates MLH1 chromatin binding, 
and cells lacking the protein develop MMR deficiency and MSI [12]. Three homozygous 
truncating mutations (c.672_673delGGinsC [p.Glu225Lysfs*4], c.1483G>T [p.E495*], 
c.394C>T [p.Arg132*]) and a splice-site mutation in MCM9 have been reported in 
consanguineous families with primary ovarian insufficiency [13-15]. The proband homozygous 
for c.672_673delGGinsC also developed early-onset CRC and mixed polyposis, and three 
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heterozygous relatives had an attenuated phenotype of late CRC or few polyps [15], indicating a 
potential role for perturbed MCM9 function contributing to the development of CRC.  
We hypothesized that genetic alterations that disrupt MCM9 helicase activity or 
interaction with MLH1 or MSH2 could result in the development of a tumor with molecular and 
pathology features consistent with Lynch syndrome. Herein, we present the first comprehensive 
screen of the MCM9 gene in a cohort of LLS patients who were recruited as part of routine care 
from family cancer clinics across Australia. 
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Materials and Methods 
 
We screened a cohort of 109 LLS patients (from a study recruiting colorectal cancer patients 
from 15 family cancer clinics in Australia, HREC/09/SVH/63 [16]) for germline mutations 
within the MCM9 gene. Informed written consent was obtained from all individual participants 
included in the study. In brief, the cohort fulfilled the following criteria: (i) Clinical suspicion of 
Lynch syndrome based on clinical/family history; (ii) Loss of MLH1 (74 patients) or MSH2 (35 
patients) immunostaining in the tumor from the proband; (iii) No pathogenic sequence mutation 
or copy number alteration in MLH1 or MSH2 as determined by Sanger sequencing and MLPA; 
(iv) No constitutional methylation of the MLH1 or MSH2 promoter as measured with 
pyrosequencing [17]. To meet criteria (iii) the patients must have first met eligibility criteria for 
germline testing according to Australia’s national guidelines [18]. The study cohort was 
therefore representative of patients who were recruited in the “real world” through a family 
cancer clinic, and who had a negative screen for germline alternations in the MMR genes. The 
cohort had a mean age of 61 years (range 16-92 years) and included 79 females, 24 males, and 6 
of unspecified gender. Only the proband was recruited from each family since they had tested 
negative in germline genetic and epigenetic screening, there was no clinical justification to 
recruit additional family members to the study. 
Genomic DNA was isolated from peripheral blood mononuclear cells by standard 
phenol-chloroform extraction or from saliva using the Oragene-DNA kit (Genotek, #OG-500). 
PCRs were performed on 20 ng of DNA using 17 primer pairs that amplified all MCM9 exons, 
the 5’UTR and splice sites (primer sequences are available upon request). PCR products were 
directly sequenced with the Big Dye Terminator v3.1 cycle sequencing kit (Applied Bio systems, 
# 4337454) and an Applied Biosystems 3730 DNA analyzer. All chromatograms were 
independently inspected by two researchers and aligned to the genome using the UCSC Genome 
Browser BLAT function.  
Variants identified in each patient were compared to the dbSNP44, 1000 Genomes Phase 
3 and ExAC variant databases. Variants were classified as follows: common single nucleotide 
polymorphisms (SNPs, population minor allele frequency (MAF) > 0.01), rare variants 
(population MAF < 0.01), novel variants (not present in any population-based database). 
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PolyPhen-2 [19], SIFT [20] and CONDEL [21] were used to predict the effect of missense 
mutations on MCM9 stability and function. 
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Results 
 
Analysis of the MCM9 gene identified a total of fifteen variants that resulted in synonymous or 
missense mutations. The variants included six common SNPs, eight rare variants and one novel 
variant (Table 1). The common SNPs and three of the rare variants were classed as not 
pathogenic because they resulted in synonymous mutations and/or had a population MAF > 0.01 
(rs12197931, rs41292552, rs151149424, rs284921, rs79670608, rs65685, rs117470188 and 
rs55779481). Although rs3751444 was classified as a common SNP (based on a MAF > 0.01) it 
was classified as possibly damaging (PoD) by PolyPhen-2. One rare variant (rs78231991) was 
predicted to be probably damaging (PrD) and one as PoD (rs78791427). The novel variant 
(c.1592T>C) was also predicted to be PoD. Further analysis with two additional in silico 
prediction programs, SIFT and CONDEL, revealed that only rs78231991 was consistently 
identified as having a deleterious effect by all programs. The variant was only present in 3.7% of 
patients (4/109). This variant was still classified as a variant of unknown significance (VUS) 
because in silico predictions and population frequency are insufficient to class a variant as 
pathogenic. No variants were located in the Walker A or R-finger motifs (Figure 1) that are 
critical for helicase activity [12, 22].  
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Discussion 
 
Our sequencing approach identified no obvious pathogenic variants in the promoter, coding 
region or splice sites of MCM9, however, we described a small number of VUSs. 
In silico prediction software, population-based variant databases and the position within 
known protein domains were used to assess the functional relevance of each VUS. PolyPhen-2 
predicts the potential impact of missense mutations on the structure and function of human 
proteins by using a number of sequence, phylogenetic, and structural features that characterize 
the amino acid substitution [19]. SIFT uses sequence conservation to predict the functional effect 
of a variant [20], whilst CONDEL integrates the output of five predictive tools [21]. None of the 
four VUS classified as possibly pathogenic using these analyses were located within important 
helicase motifs of MCM9, however, we can’t exclude the possibility that they affect MCM9 
function or stability. The sensitivity and specificity of each algorithm may affect the predictions 
made by the in silico tools, and we acknowledge that a limitation of our study was the lack of 
functional assays to investigate the effect of the variants on MCM9.  We also acknowledge that 
our strategy would not have detected copy number or structural variations in MCM9 so the total 
number of mutations may have been underestimated, and it is possible that cancer in some of 
these patients is caused by somatic mutations in the MMR genes or other unexplored 
components of the MMR complex. The cohort also didn’t include MSI cases with normal MMR 
staining, a phenotype that would also be predicted by loss of MCM9 function. A further 
limitation of the study was that the immunohistochemical and molecular data on the cohort was 
provided through report forms and was not repeated centrally.  
In summary, this study is the first comprehensive screen of point mutations and indels in 
the MCM9 gene in patients with LLS. Pathogenic variants were very rare in this cohort, 
indicating that germline mutations in MCM9 are unlikely to explain cancer predisposition in LLS 
patients recruited in routine practice through family cancer clinics where pre-specified eligibility 
for germline testing is determined by national guidelines.   
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Figure 1 Location of variants in the MCM9 gene. A schematic of the MCM9 gene (upper panel) 
showing the location of PCR amplicons for sequencing (middle panel) and the position of 
variants (1-16, see Table 1) within the MCM9 protein (lower panel).  
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 Table 1. Variants identified within MCM9 in the cohort of LLS patients (n=109) 
 
†GRCh38/hg38 
Consequence: S, synonymous; M, missense (Protein) 
Polyphen: PrD, probably damaging; PoD, possibly damaging; B, benign. 
SIFT: Tol., tolerated; Del, deleterious; Und, undetermined. 
CONDEL: Neut., neutral; Med.; medium. 
* Based on 218 chromosomes (109 patients). 
n.p., not present in database; n/a, not applicable; ±, standard deviation; F, female; M, male; U, unspecified gender. 
 
 
 
 
Variant  
number 
Variant ID Location Consequence In silico 
predictions 
Population variant 
allele frequency 
Cohort variant  
allele 
frequency* 
 
Average age of 
cancer onset 
(number of 
individuals) 
Number of 
individuals of 
each sex 
(F/M/U) 
Number of individuals 
with loss of MMR 
protein staining 
(MLH1/MSH2) 
Co-ordinate 
(chr. 6)† 
Exon  cDNA Protein PolyPhen SIFT CON
DEL 
dpSNP144/ 
1000G Ph.3 
ExAC     
1 rs12197931 118,923,859 2 c.573G>A p.Ser191Ser (S) n/a Tol. n/a 0.098 0.059 0.04 64±17 (9) 6/2/1 6/3 
2 rs41292552 118,917,739 4 c.726G>A p.Gly242Gly (S) n/a Tol. n/a 0.014 0.022 0.03 62±22 (6) 3/3/0 4/2 
3 rs78231991 118,913,414 5 c.911A>G p.Asn304Ser (M) PrD Del. Med. 0.003 0.003 0.02 48±12 (4) 2/2/0 3/1 
4 rs151149424 118,856,424 7 c.1272G>A p.Arg424Arg (S) n/a Tol. n/a 0.001 0.003 0.009 70±13 (2) 1/1/0 1/1 
5 rs9387607 118,829,055 8 c.1521A>T p.Glu507Asp (M) B Tol. Neut. 0.014 0.006 0.005 52 (1) 1/0/0 1 
6 Novel 118,828,067 9 c.1592T>C p.Ile531Thr (M) PoD Und. Low n.p. n.p. 0.005 52 (1) 1/0/0 1 
7 rs284921 118,827,986 9 c.1673G>C p.Cys558Ser (M) B Tol. Neut. 0.089 0.85 0.84 61±17 (104) 76/22/6 71/33 
8 rs78791427 118,816,282 12 c.1974G>T p.Gln658His (M) PoD Tol. Low 0.003 0.008 0.014 75±9 (3) 2/1/0 2/1 
9 rs75607191 118,816,260 12 c.1996G>A p.Arg666Trp (M) B Del. Low 0.003 0.005 0.005 70 (1) 0/1/0 0/1 
10 rs79670608 118,815,984 12 c.2272A>G p.Thr758Ala (M) B Tol. Med. 0.018 0.029 0.032 66±14 (7) 6/1/0 5/2 
11 rs65685 118,815,596 12 c.2660T>G p.Met887Arg (M) B Tol. Neut. 0.091 0.152 0.17  58±19 (32) 22/8/2 19/13 
12 rs3751444 118,815,563 12 c.2693C>T p.Ser898Phe (M) PoD Tol. Med. 0.01 0.015 0.005 38 (1) 0/0/1 1/0 
13 rs117470188 118,815,367 12 c.2889C>T p.Asp963Asp (S) n/a Tol. n/a 0.005 0.011 0.009 80±13 (2) 1/0/1 2/0 
14 rs55779481 118,815,355 12 c.2901G>A p.Pro967Pro (S) n/a Tol n/a 0.003 0.005 0.009 80±13 (2) 1/0/1 2/0 
15 rs61742362 118,814,970 12 c.3286A>G p.Met1096Val (M) B Tol. Neut. 0 0.002 0.005 56 (1) 1/0/0 1/0 
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